Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Edelstein

Gastroenterology Beverly Hills, CA Medical Doctor

NPI 1669488821 CMS profile 75139

150 N Robertson Blvd, Suite 204, Beverly Hills, CA 90211

Open in the dashboard

General payments

$5,499

232 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marc Edelstein of Beverly Hills, CA is reported in the CMS Open Payments database as having received $5,499 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $834 35
2024 General $1,392 62
2023 General $1,051 41
2022 General $655 26
2021 General $546 24
2020 General $225 10
2019 General $795 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Edelstein
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Marc Edelstein were reported at $834. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Marc Edelstein Gastroenterology median Middle half National median
2019 $795 $417 $126–$1,100 $163
2020 $225 $224 $74–$624 $114
2021 $546 $352 $106–$1,054 $132
2022 $655 $448 $129–$1,270 $149
2023 $1,051 $533 $150–$1,390 $160
2024 $1,392 $605 $160–$1,606 $164
2025 $834 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $1,871 92 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $651 32 payments
  3. AbbVie, Inc. $433 15 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $415 20 payments
  5. QOL Medical, LLC $400 15 payments
  6. Regeneron Healthcare Solutions, Inc. $240 10 payments
  7. Allergan Inc. $199 7 payments
  8. Exact Sciences Corporation $187 7 payments
  9. Genzyme Corporation $174 6 payments
  10. Ferring Pharmaceuticals Inc. $140 2 payments
  11. Other $790 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,446 227 payments
  2. Education $53 5 payments
Products named General payments · program years 2019–2025
  1. INJECTAFER $1,746 86 payments
  2. ENTYVIO $524 27 payments
  3. LINZESS $269 9 payments
  4. XIFAXAN $221 12 payments
  5. DUPIXENT Inflammation And Immunology $201 8 payments
  6. Cologuard Collection Kit $187 7 payments
  7. DUPIXENT Immunology $174 6 payments
  8. VIBERZI $157 3 payments
  9. TRULANCE $152 3 payments
  10. Sucraid $151 5 payments
  11. Other $1,870 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

837

Median for Internal Medicine: 777

Drug cost

$161,243

Median for Internal Medicine: $73,373

Branded share of claims

29.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 29 $51,417
Xifaxan Rifaximin Brand 22 $51,355
Dexilant Dexlansoprazole Brand 30 $14,134
Linzess Linaclotide Brand 18 $11,725
Motegrity Prucalopride Succinate Brand 18 $9,166
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 106 $6,698
Dexlansoprazole Dr Dexlansoprazole Brand 11 $4,448
Omeprazole Generic 183 $2,987
Pantoprazole Sodium Generic 130 $2,760
Mesalamine Generic 12 $1,883

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$122,945

Medicare's payments for the services billed

Medicare patients

325

Average age 77

Services billed

1,679

170 women, 155 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 56%
Ischemic heart disease 50%
Diabetes 24%
Osteoporosis 23%
Cancer 20%
Chronic kidney disease 19%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INJECTAFER
  • Daiichi Sankyo Inc. $501
$501 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $258
$258 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $100
  • GENZYME CORPORATION $27
$127 — —
CREON
  • AbbVie, Inc. $82
$82 29 —
Sucraid
  • QOL Medical, LLC $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record